Page 73 - Škrgat, Sabina, ed. 2023. Severe Asthma Forum - Monitoring and Treatable Traits in Severe Asthma. Koper: University of Primorska Press. Severe Asthma Forum, 2
P. 73
Di Bona D, Fiorino I, Taurino M, et al. 23. Kavanagh JE, d’Ancona G, Elstad M, 73
Long-term “real-life” safety of omal- et al. Real-world effectiveness and the
izumab in patients with severe un- characteristics of a “super-responder” mon i tor i ng a n d eva luat ion of t h e r a peu t ic r e sponse i n pat i e n ts w i t h sev e r e a st h m a on biologic s
controlled asthma: A nine-year study. to mepolizumab in severe eosinophil-
Respir Med. 2017 Sep:130:55-60. ic asthma. Chest. Aug 2020;158(2):491-
500.
15. Ortega HG, Liu MC, Pavord ID, et
al. Mepolizumab treatment in patients 24. Kavanagh JE, Hearn AP, Dhariwal J, et
with severe eosinophilic asthma. N Engl al. Real-World Effectiveness of Benral-
J Med. 2014 Sep 25;371(13):1198-207. izumab in Severe Eosinophilic Asthma.
Chest. 2021 Feb;159(2):496-506.
16. van Toor JJ, van der Mark SC, Kappen
JH, et al. Mepolizumab add-on therapy 25. Numata T, Araya J, Miyagawa H et al.
in a real world cohort of patients with Effectiveness of Switching Biologics for
severe eosinophilic asthma: response Severe Asthma Patients in Japan: A Sin-
rate, effectiveness, and safety. J Asthma. gle-Center Retrospective Study. J Asth-
2021 May;58(5):651-8. ma Allergy. 2021 Jun 3:14:609-618.
17. Caminati M, Cegolon L, Vianello A, 26. Eger K, Kroes JA, ten Brinke A, et al.
et al. Mepolizumab for severe eosino- Long-Term Therapy Response to An-
philic asthma: a real-world snapshot ti-IL-5 Biologics in Severe Asthma- A
on clinical markers and timing of re- Real-Life Evaluation. J Allergy Clin Im-
sponse. Expert Rev Respir Med. 2019 munol Pract. Mar 2021;9(3):1194-200.
Dec;13(12):1205-12.
27. Haldar P, Brightling CE, Singapuri A,
18. Harrison T, Canonica GW, Chupp G, et al. Outcomes after cessation of me-
et al. Real-world mepolizumab in the polizumab therapy in severe eosino-
prospective severe asthma REALI- philic asthma: a 12-month follow-up
TI-A study: initial analysis. Eur Respir analysis. J Allergy Clin Immunol. 2014
J. 2020 Oct 15;56(4):2000151. doi: Mar;133(3):921-3.
10.1183/13993003.00151-2020.
28. Ledford D, Busse W, Trzaskoma B, et
19. Jackson DJ, Korn S, Mathur SK, et al. al. A randomized multicenter study
Safety of Eosinophil-Depleting Thera- evaluating Xolair persistence of re-
py for Severe, Eosinophilic Asthma: Fo- sponse after long-term therapy. J Aller-
cus on Benralizumab. Drug Saf. 2020 gy Clin Immunol. 2017 Jul;140(1):162-
May;43(5):409-25. 9.e2.
20. Virchow JC, Katial R, Brusselle GG, et 29. Pepper AN, Hanania NA, Humbert M
al. Safety of reslizumab in uncontrolled et al. How to Assess Effectiveness of Bi-
asthma with eosinophilia: a pooled ologics for Asthma and What Steps to
analysis from 6 trials. J Allergy Clin Im- Take When There Is Not Benefit. J Al-
munol Pract. 2020 Feb;8(2):540-8.e.1. lergy Clinin Immunol Pract. 2021
Mar;9(3):1081-8
21. Halling AS, Loft N, Silverberg JI, et al.
Real-world evidence of dupilumab ef- 30. Drick N, Milger K, Seeliger B, et al.
ficacy and risk of adverse events: A sys- Switch from IL-5 to IL-5-Receptor α
tematic review and meta-analysis. J Am Antibody Treatment in Severe Eosino-
Acad Dermatol. 2021 Jan;84(1):139-47. philic Asthma. J Asthma Allergy. 2020
Nov 11:13:605-614..
22. Menzies-Gow A, Corren J, Bourdin A,
et al. Tezepelumab in Adults and Ad- 31. McDowell PJ, Diver S, Yang F, et al.
olescents with Severe, Uncontrolled Medical Research Council: Refracto-
Asthma. N Engl J Med. 2021 May ry Asthma Stratification Programme
13;384(19):1800-9. (RASP-UK Consortium). The inflam-
Long-term “real-life” safety of omal- et al. Real-world effectiveness and the
izumab in patients with severe un- characteristics of a “super-responder” mon i tor i ng a n d eva luat ion of t h e r a peu t ic r e sponse i n pat i e n ts w i t h sev e r e a st h m a on biologic s
controlled asthma: A nine-year study. to mepolizumab in severe eosinophil-
Respir Med. 2017 Sep:130:55-60. ic asthma. Chest. Aug 2020;158(2):491-
500.
15. Ortega HG, Liu MC, Pavord ID, et
al. Mepolizumab treatment in patients 24. Kavanagh JE, Hearn AP, Dhariwal J, et
with severe eosinophilic asthma. N Engl al. Real-World Effectiveness of Benral-
J Med. 2014 Sep 25;371(13):1198-207. izumab in Severe Eosinophilic Asthma.
Chest. 2021 Feb;159(2):496-506.
16. van Toor JJ, van der Mark SC, Kappen
JH, et al. Mepolizumab add-on therapy 25. Numata T, Araya J, Miyagawa H et al.
in a real world cohort of patients with Effectiveness of Switching Biologics for
severe eosinophilic asthma: response Severe Asthma Patients in Japan: A Sin-
rate, effectiveness, and safety. J Asthma. gle-Center Retrospective Study. J Asth-
2021 May;58(5):651-8. ma Allergy. 2021 Jun 3:14:609-618.
17. Caminati M, Cegolon L, Vianello A, 26. Eger K, Kroes JA, ten Brinke A, et al.
et al. Mepolizumab for severe eosino- Long-Term Therapy Response to An-
philic asthma: a real-world snapshot ti-IL-5 Biologics in Severe Asthma- A
on clinical markers and timing of re- Real-Life Evaluation. J Allergy Clin Im-
sponse. Expert Rev Respir Med. 2019 munol Pract. Mar 2021;9(3):1194-200.
Dec;13(12):1205-12.
27. Haldar P, Brightling CE, Singapuri A,
18. Harrison T, Canonica GW, Chupp G, et al. Outcomes after cessation of me-
et al. Real-world mepolizumab in the polizumab therapy in severe eosino-
prospective severe asthma REALI- philic asthma: a 12-month follow-up
TI-A study: initial analysis. Eur Respir analysis. J Allergy Clin Immunol. 2014
J. 2020 Oct 15;56(4):2000151. doi: Mar;133(3):921-3.
10.1183/13993003.00151-2020.
28. Ledford D, Busse W, Trzaskoma B, et
19. Jackson DJ, Korn S, Mathur SK, et al. al. A randomized multicenter study
Safety of Eosinophil-Depleting Thera- evaluating Xolair persistence of re-
py for Severe, Eosinophilic Asthma: Fo- sponse after long-term therapy. J Aller-
cus on Benralizumab. Drug Saf. 2020 gy Clin Immunol. 2017 Jul;140(1):162-
May;43(5):409-25. 9.e2.
20. Virchow JC, Katial R, Brusselle GG, et 29. Pepper AN, Hanania NA, Humbert M
al. Safety of reslizumab in uncontrolled et al. How to Assess Effectiveness of Bi-
asthma with eosinophilia: a pooled ologics for Asthma and What Steps to
analysis from 6 trials. J Allergy Clin Im- Take When There Is Not Benefit. J Al-
munol Pract. 2020 Feb;8(2):540-8.e.1. lergy Clinin Immunol Pract. 2021
Mar;9(3):1081-8
21. Halling AS, Loft N, Silverberg JI, et al.
Real-world evidence of dupilumab ef- 30. Drick N, Milger K, Seeliger B, et al.
ficacy and risk of adverse events: A sys- Switch from IL-5 to IL-5-Receptor α
tematic review and meta-analysis. J Am Antibody Treatment in Severe Eosino-
Acad Dermatol. 2021 Jan;84(1):139-47. philic Asthma. J Asthma Allergy. 2020
Nov 11:13:605-614..
22. Menzies-Gow A, Corren J, Bourdin A,
et al. Tezepelumab in Adults and Ad- 31. McDowell PJ, Diver S, Yang F, et al.
olescents with Severe, Uncontrolled Medical Research Council: Refracto-
Asthma. N Engl J Med. 2021 May ry Asthma Stratification Programme
13;384(19):1800-9. (RASP-UK Consortium). The inflam-
